Market Overview

Merck Begins Phase II/III Study of Investigational BACE Inhibitor, MK-8931

Related MRK
Merck Announces That IMPROVE-IT Achieved Primary Endpoint; Data To Be Presented At American Heart Association Scientific Sessions Today
Merck Announces Results From Phase 2 Study Of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir In Genotype 1 Infected Treatment-Naïve And Difficult-To-Cure Patients
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

From Earlier: Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease. MK-8931 is Merck's novel investigational oral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor, and is the first with this mechanism to advance to this stage of clinical research. The global, multi-center study, called EPOCH, is designed to initially evaluate the safety of MK-8931 in a cohort of 200 patients prior to advancing into a larger Phase III study.

Posted-In: News FDA

 

Related Articles (MRK)

Around the Web, We're Loving...

Get Benzinga's Newsletters